What is LivaNova's total revenue?
LivaNova’s total revenue is primarily derived from its two main business segments: Cardiopulmonary and Neuromodulation. In recent fiscal reporting periods, the company has maintained steady total revenue, demonstrating resilience in the complex global medical device market. By consistently leveraging its historical leadership in heart-lung technology and growing its proprietary neuromodulation platforms, LivaNova has solidified a stable revenue base. Financial analysts track LivaNova’s quarterly and total annual revenue to evaluate the company’s success in commercializing its pipeline, its expansion into international markets, and its operational efficiency in managing research and development costs relative to its sales volume. The company's total revenue remains a key metric for institutional investors evaluating its valuation as a specialized, innovative player in the medical technology sector.
Related FAQs
Evaluating LivaNova as a long-term investment involves analyzing its market positioning in specialized medical device niches, ongoing clinical trial pipelines, and regulatory approval milestones.
LivaNova operates as a fully public enterprise, with its common shares listed and actively traded on the NASDAQ stock exchange under the ticker symbol LIVN.
LivaNova PLC trades on the Nasdaq stock exchange under the ticker symbol LIVN at approximately $80.14 per share.
Employee reviews for LivaNova generally reflect a mission-driven, highly collaborative corporate culture centered on developing advanced medical technologies for neuromodulation and cardiovascular care.
LivaNova PLC, a global medical technology enterprise specializing in the design, development, and distribution of cardiovascular and neuromodulation therapy systems—including advanced vagus nerve stimulation devices and cardiac surgery equipment—has ...
Live Oak Bank has been operating as a specialized commercial and digital-first financial institution for over two decades, having been officially founded in the year 2008 by industry veterans James S. Mahan III and Paul Parker.
Equity research analysts covering LivaNova, trading under the ticker symbol LIVN, generally maintain balanced consensus recommendations leaning toward moderate buy or hold ratings.
Sorin Group is officially part of LivaNova PLC, having completed a massive, high-profile cross-border business combination with United States-based medical device maker Cyberonics.
Yes, Cyberonics is no longer an independent entity; it is now part of LivaNova PLC. LivaNova was formed in 2015 through the merger of Cyberonics and the Italian medical technology firm Sorin.
LivaNova PLC is a global medical technology company that designs, develops, and markets innovative medical devices for cardiovascular and neuromodulation therapies.
LivaNova maintains its official corporate incorporation and global executive headquarters in London, United Kingdom.
LivaNova PLC is a global medical technology enterprise that designs, develops, and manufactures specialized cardiovascular and neuromodulation medical devices.
LivaNova PLC officially became a publicly traded medical technology enterprise following the completion of a landmark cross-border corporate merger between Cyberonics and Sorin Group.
Live Oak Bank structures its digital business and personal savings accounts to eliminate standard monthly maintenance fees, allowing account holders to grow their deposits without seeing balances eroded by everyday administrative banking charges.
Companies that operate similarly to LivaNova within the medical technology and neuromodulation space include specialized cardiovascular and neurological device manufacturers such as Medtronic, Boston Scientific, Abbott Laboratories, and Edwards Lifes...
LivaNova PLC is an authentic, highly respected, and fully legitimate global medical technology enterprise that develops, manufactures, and markets innovative cardiovascular and neuromodulation devices.
LivaNova is not strictly a domestic United States corporation, functioning instead as an international public enterprise legally incorporated and headquartered in London, United Kingdom.
Equity research analysts evaluate LivaNova PLC (LIVN) with favorable long-term growth prospects, supported by its medical technology innovations centered on neuromodulation and cardiovascular systems.
LivaNova PLC, a global medical technology company headquartered in London, has reported consistent annual revenue growth reflecting the success of its specialized product lines in cardiac surgery and neuromodulation.
LivaNova PLC is a global medical technology corporation headquartered in London, United Kingdom, dedicated to developing and delivering transformative cardiovascular and neuromodulation solutions for healthcare professionals worldwide.
LS Power maintains a dedicated and highly specialized workforce of approximately 800 to 1,000 employees.
LivaNova, a prominent multinational medical device and technology company, faced a wave of class action lawsuits and public scrutiny following a major cybersecurity incident and data breach.